Pulmonx Corp
NASDAQ:LUNG
Pulmonx Corp
Research & Development
Pulmonx Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pulmonx Corp
NASDAQ:LUNG
|
Research & Development
-$18.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Research & Development
-$62.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Research & Development
-$88.8m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-18%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Research & Development
-$369.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-20%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Research & Development
-$165.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-26%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Research & Development
-$96m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
Pulmonx Corp
Glance View
Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
See Also
What is Pulmonx Corp's Research & Development?
Research & Development
-18.9m
USD
Based on the financial report for Sep 30, 2025, Pulmonx Corp's Research & Development amounts to -18.9m USD.
What is Pulmonx Corp's Research & Development growth rate?
Research & Development CAGR 5Y
-23%
Over the last year, the Research & Development growth was -20%. The average annual Research & Development growth rates for Pulmonx Corp have been -8% over the past three years , -23% over the past five years .
